DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$3.09 USD
+0.19 (6.55%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $3.08 -0.01 (-0.32%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DMAC 3.09 +0.19(6.55%)
Will DMAC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DMAC
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
Other News for DMAC
Biotech Alert: Searches spiking for these stocks today
Diamedica Therapeutics (DMAC) Receives a Buy from Craig-Hallum
DiaMedica Therapeutics Announces $11.8 Million Private Placement
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
Lake Street Remains a Buy on Diamedica Therapeutics (DMAC)